Biocon gets EIR from USFDA for API facility

06 Aug 2024 Evaluate

Biocon has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (USFDA), for its API facility (Site 5), located at Visakhapatnam, Andhra Pradesh. This is based on a GMP inspection conducted by the agency between June 17 and June 21, 2024. Biocon remains committed to Quality, Safety & Efficacy of the products manufactured.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

380.70 2.90 (0.77%)
16-Feb-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1703.45
Dr. Reddys Lab 1267.45
Cipla 1357.00
Zydus Lifesciences 910.00
Lupin 2216.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×